Antiplatelet therapy for transient ischemic attack

Journal of Clinical Hypertension

Volumn 14, Issue 2, 2012, Pages 103-111

  Acelajado, Maria Czarina ^a   Oparil, Suzanne ^a  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE;

ALCOHOLISM; ANTICOAGULANT THERAPY; BLEEDING; BRAIN ATHEROSCLEROSIS; CARDIOMYOPATHY; CIGARETTE SMOKING; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); OBESITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VALVULAR HEART DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BRAIN ISCHEMIA; COGNITION DISORDERS; DIFFUSION MAGNETIC RESONANCE IMAGING; DIPYRIDAMOLE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; PROGNOSIS; SECONDARY PREVENTION; STROKE; TICLOPIDINE;

EID: 84856248993     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00571.x     Document Type: Review

References (40)

1. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990;21:637-676.
2. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009;40:2276-2293.
3. Shah SH, Saver JL, Kidwell CS, et al. A multicenter, pooled, patient-level data analysis of diffusion-weighted MRI in TIA patients. Stroke. 2007;38:463.
4. Johnston SC, Fayad PB, Gorelick PB, et al. Prevalence and knowledge of transient ischemic attack among US adults. Neurology. 2003;60:1429-1434.
5. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817-820.
6. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901-2906.
7. Giles MF, Rothwell PM. Risk of stroke early after transient ischemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007;6:1063-1072.
8. Wu CM, McLaughlin K, Lorenzetti DL, et al. Early risk of stroke after transient ischemic attack. A systematic review and meta-analysis. Arch Intern Med. 2007;167:2417-2422.
9. Chandratheva A, Meta Z, Geraghty OZ, et al. Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology. 2009;72:1941-1947.
10. Weimar C, Benemann J, Huber R, et al. Long-term mortality and risk of stroke after transient ischemic attack. J Neurol. 2009;256:639-644.
11. Clark TG, Murphy MFG, Rothwell PM. Long-term risks of stroke, myocardial infarction, and vascular death in "low risk" patients with a non-recent transient ischemic attack. J Neurol Neurosurg Psychiatry. 2003;74:577-580.
12. Bos MJ, van Rijn MJE, Witteman JCM, et al. Incidence and prognosis of transient neurological attacks. JAMA. 2007;298:2877-2885.
13. Johnson P, Rosewell M, James MA. How good is the management of vascular risk after stroke, transient ischemic attack or carotid endarterectomy? Cerebrovasc Dis. 2007;23:156-161.
14. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849-1860.
15. Lievre M, Cucherat M. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis. Fundam Clin Pharmacol. 2010;24(3):385-391.
16. Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischemic stroke. Cochrane Database Syst Rev. 2008:CD000029. doi:.
17. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-276.
18. Ridker PM, Cook NR, Lee I, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
19. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
20. Aronow HD, Califf RM, Harrington RA, et al. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO trial). Am J Cardiol. 2008;102:1285-1290.
21. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose with clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379-386.
22. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs. 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261-1266.
23. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ. 2002;324:71-86.
25. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
26. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-1673.
27. DeSchryver E, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2007;18:CD001820. doi:.
28. Bristol-Myers Squibb/Sanofi Pharmaceuticals. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals; 2009.
29. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
30. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patient (MATCH): randomised, double-blind placebo-controlled trial. Lancet. 2004;364:331-367.
31. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
32. FDA Drug Safety Communication. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Accessed April 1, 2010.
33. Sandercock PAG, Gibson LM, Liu M. Anticoagulants for preventing recurrence following presumed non-cardioembolicischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2009;15:CD000248. doi:.
34. The ESPRIT Study Group. Medium-intensity oral anticoagulants versus aspirin after cerebral ischemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol. 2007;6:115-124.
35. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
36. Blackshear JL, Halperin JL, Hart RG, et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
37. Saxena R, Kuodstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;18:CD000187. doi:.
38. Serebruany VL, Malinin AI, Ferguson JJ. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129, 314 patients. Fundam Clin Pharmacol. 2008;22:315-321.
39. Usman MHU, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009;103:1107-1112.
40. Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 (Oxford Vascular Study). Lancet. 2004;363:925-933.